DGCI Starts Monitoring Remedesivir To Curb Black Marketingby Dolly K. Digital Marketing Executive
DCGI or Drugs Controller General of India recently directed State Licensing Authorities or SLAs to keep an eye on the availability of Remdesivir injections and prohibit its advertisement. It has been done to make sure they are available for supply. Moreover, taking timely action helps in preventing hoarding as well as black marketing.
It has been noticed by the union health ministry that places like Thane and Mumbai in Maharashtra; Bhopal, Indore and Gwalior in the State of Madhya Pradesh and Ahmedabad, along with Surat and Rajkot in Gujarat are suffering from a shortage of Remdesivir injections. Seeing this, State licensing authorities were directed by DCGI that they must start proper action to make sure Remdesivir injections are available for public and private hospitals.
All SLA were also instructed to direct the enforcement staff to keep consistent monitoring of the whole situation and keep very strict vigilance to ensure the required availability of Remdesivir injections and prohibit its advertisement and black marketing.
All the actions taken in this matter should be informed to the DCGI office as early as possible. To stop hoarding and black marketing the Remdesivir injections, the Maharashtra Food and Drug Administration (FDA) has recently notified all the manufacturers of Remdesivir injections to decrease the wholesale price of the drug and at the same time has proposed to the National Pharmaceutical Pricing Authority to monitor the price movement.
Recently, the Maharashtra FDA commissioner conducted a meeting with all the senior officials of the Mumbai headquarters to discuss ways for decreasing the big gap between the wholesale selling price and the maximum retail price of Remdesivir injection. They also discussed different ways of making this drug available to all patients at affordable rates.
The Maharashtra FDA is doing a regular review of the Remdesivir injection availability along with other kinds of drugs in the State. Sh. Rajendra Shingane, Maharashtra FDA Minister and Sh. Saurabh Vijay, secretary of Department of Medical Education and Drugs Maharashtra, has given notification to take action against the price rise of Remdesivir injection.
At present, there are six big manufacturers of Remdesivir injection 100 mg in the whole market. To give you an idea, Dr Reddy’s Labs REDYX costs INR 2,700, Cipla’s CIPREMI costs INR 3,000 and Cadila Healthcare’s REMDAC costs INR 899. These rates have been recently revised by manufacturers and have been reduced significantly to benefit the common people.
The price of Remedesivir injections was exorbitant just a few weeks ago. It was being supplied to wholesalers and hospitals at a rate between Rs.8000 to Rs.12000. In such a scenario, there was an uproar from several quarters about the financial stress imposed on patients by increasing the maximum retail price of the injection.
Thus, to curb this, DCGI has taken action by reviewing the actual scenario and imposing monitoring programmes.
Created on May 14th 2021 06:17. Viewed 19 times.